News item - CANCERactive immunotherapy is the hot topic in cancer treatment - with scientists arguing that it is the fourth leg of orthodox medicine, alongside chemotherapy, radiotherapy and surgery
For example Lilly, Glaxo, Roche and AstraZeneca each have deals with biotech company Immunocore.
All hope to develop cancer therapies that direct a patient’s T-cells to target cancerous cells, so effectively using the body’s own immune system to fight the disease.
Go To: CANCERactive Immunotherapy - The New Frontier - Review
Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor against Cancer (ImmTAC) is the common interest.
Current leaders in the field are Merck & Co, which has an anti-PD1 antibody pembrolizumab and Bristol-Myers Squibb, which has an anti-PD1 drug Opdivo (nivolumab).
Dr. Jan Lundberg, president of Lilly Research Laboratories, commented on the company’s confidence in cancer immunotherapies.
"The major goal and challenge of cancer immunotherapy is to direct the immune system to recognise and destroy cancer,” he said. “We believe Immunocore’s ImmTAC platform has the potential to do just that.”
Readers of this article also read:
Go To: A review of Dendritic cell therapy and immunotherapy
Go To: First bladder cancer immunotherapy drug
Go To: Gc-Maf. Natural Immunotherapy?
Go To: Prostate cancer immunotherapy likely soon